媒体报道阿里巴巴准备推进旗下芯片业务"平头哥"单独上市，摩根大通对"报道时机"感到意外。 追风交易台消息，1月23日，摩根大通中国证券研究主管姚橙的团队发表研报，参照同业估值测算，"平 头哥"的潜在估值可能在250亿至620亿美元之间，约占阿里当前市值的6%到14%。 但报告明确指出，这个数字高度依赖未来实际的业务规模、竞争力以及最终的交易结构。 分析师认为当前市场更聚焦于验证阿里云与AI核心业务能否扎实兑现的阶段。公司选择重启"价值释 放"叙事，更像是一种战略沟通姿态，试图展示资产价值。 250-620亿美元怎么算出来的 针对"平头哥"的潜在估值，摩根大通给出了一个宽泛的区间：250亿至620亿美元，约占阿里巴巴当前市 值的6%至14%。 报告强调，这是一个示意性的"选择权价值"估算，通过激进的2026年收入替代指标，将其与昆仑芯、寒 武纪等国内同业进行粗略对比得出的。 这个区间对三个因素高度敏感：实际对外出售的资产是什么、与国内外替代产品相比的竞争力如何、最 终交易结构怎么设计。 换句话说，这个数字更像是在回答"如果平头哥成为单独估值资产，市场会给多少钱"，而不是基于完整 芯片业务基本面的建模。 研报坦承 ...

Group 1 - The core viewpoint is that Jiaxin International Resources (03858) is at a critical value release point, possessing world-class core assets, and is a rare pure tungsten mining target in the market, with a high safety margin and attractiveness in its current stock price [1] - The company is headquartered in Kazakhstan and focuses on tungsten mining, with its core asset being the Bakuta tungsten project. Its business model covers the entire chain of exploration, mining, processing, and sales of tungsten concentrate [2] - The company plans to explore more investment opportunities in non-ferrous metal resources in Central Asia, following the commencement of commercial production at the Bakuta tungsten mine in April 2025 [2] Group 2 - The company has a unique integrated model in its biomass business, which includes biomass direct combustion power generation, biomass heating, and integrated biomass and waste power generation, effectively reducing overall development and operational costs [3] - The company currently handles 42 types of hazardous waste, with a project IRR exceeding 20%. The hazardous waste disposal prices range from 2,000 to 17,000 yuan per ton, with an average price of 2,732 yuan per ton in 2017, reflecting a year-on-year increase of 13.4% [4]

Core Viewpoint - The article discusses the challenges faced by Medtronic, including stagnation in growth, innovation fatigue, and pressure from activist investors, while exploring the potential for restructuring or revitalization [2][4]. Group 1: Activist Investor Involvement - Elliott Investment Management has entered Medtronic's shareholder list, advocating for a reassessment of the business portfolio and a focus on core assets to enhance shareholder returns [6][7]. - The entry of Elliott reflects a broader trend where undervalued large companies are pressured to divest non-core assets and improve capital efficiency [7][8]. - Medtronic's valuation disadvantage compared to peers indicates investor concerns regarding its management structure and innovation efficiency [8][9]. Group 2: Growth and Innovation Challenges - Medtronic's issues are traced back to the 2015 acquisition of Covidien, which has led to integration difficulties and cultural clashes [10][11]. - Financially, Medtronic reported approximately $32.3 billion in revenue for FY2024, with a net profit of about $5.1 billion, but its growth rate of 3% is below industry peers [11][12]. - The company's R&D spending of $2.6 billion represents only 8.1% of revenue, lower than competitors, indicating a slowdown in innovation output [14][15]. Group 3: Investor Perspective - Investors view Medtronic as a "sleeping giant," with stable financials but lacking growth appeal, as evidenced by a total shareholder return of less than 4% over the past five years [15][16]. - There is a demand for not just cost optimization but also significant innovation to change the valuation narrative [16][19]. Group 4: CEO's Response - CEO Geoff Martha asserts that Medtronic is in an "Innovation Super Cycle," with significant new products expected to launch between 2025 and 2027 [16][20]. - Martha emphasizes that the company's focus is on portfolio reshaping to enhance innovation rather than breaking up the company [19][20]. - The management is undergoing a dual reboot of structure and personnel to improve decision-making speed and execution [22][23]. Group 5: Future Directions - Medtronic aims to focus on financial recovery through divesting low-margin businesses and simplifying its organizational structure [23][24]. - The company is also working on bringing high-tech platforms to market, although the timeline for significant sales remains extended [24][25]. - The shift in focus from expansion to innovation reflects a recalibration towards core technological strengths, with the challenge of balancing innovation delivery and capital returns [25].